<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02105961</url>
  </required_header>
  <id_info>
    <org_study_id>117113</org_study_id>
    <nct_id>NCT02105961</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centered, randomized, placebo-controlled, double-blind, parallel group, trial
      evaluating 2 doses of mepolizumab against placebo given every 4 weeks through subcutaneous
      (SC) injection. In severe COPD subjects, sputum eosinophils levels are elevated to similar
      levels as those seen in severe asthmatics. It is hypothesized that the reduction of
      eosinophils with mepolizumab in COPD subjects would translate into a reduction of COPD
      exacerbations. The study will evaluate the efficacy and safety of mepolizumab, in subjects
      who are at or above the baseline blood eosinophil count of at least 150 cells/microliters who
      exacerbate despite regular use of maximal tolerated therapy, appropriate for severe COPD
      subjects, in the 12 months prior to study start. In total, 660 subjects will be randomized in
      1:1:1 ratio to receive mepolizumab 300 mg, mepolizumab 100mg, or placebo administered SC. The
      total duration of subject participation will be approximately 62 weeks, consisting of a 1 to
      2 week screening period, 52-week treatment period and 8-week follow-up period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2014</start_date>
  <completion_date type="Actual">January 16, 2017</completion_date>
  <primary_completion_date type="Actual">January 16, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Moderate or Severe Exacerbations</measure>
    <time_frame>From randomization to Week 52</time_frame>
    <description>Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (&gt;=24 hours) or result in death. Moderate and severe exacerbations occurring from the start of investigational product (IP) up to the Week 52 visit, including exacerbations reported after early discontinuation from IP by participants who remained in the study, were included in the analysis. The analysis was performed on the modified intent-to-treat (mITT) Population (all randomized participants who received at least one dose of study treatment).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Moderate/Severe Exacerbation</measure>
    <time_frame>From randomization to Week 52</time_frame>
    <description>Kaplan Meier estimates of the probability of a moderate or severe exacerbation are expressed as the percentage of participants with an exacerbation over time (by Week 8, 16, 24, 32, 40, 48, 52). Analysis of time to first moderate/severe exacerbation was performed on the mITT population and included exacerbations reported on-treatment and those reported after early discontinuation from IP by participants who remained in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of COPD Exacerbations Requiring Emergency Department (ED) Visits and/or Hospitalizations (Hosp)</measure>
    <time_frame>From randomization to Week 52</time_frame>
    <description>COPD exacerbations requiring an ED visit and/or hosp occurring from the start of IP up to the Week 52 visit, including exacerbations reported after early discontinuation from IP by participants who remained in the study, were included in the analysis. This analysis was performed on the mITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Total St. George's Respiratory Questionnaire (SGRQ) Score</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The SGRQ for COPD is a 40-item questionnaire derived from the original SGRQ , designed to measure health impairment by addressing the frequency of respiratory symptoms and current state of the participant. SGRQ Total Scores range from 0 to 100 with higher scores indicating worse health-related quality of life and reductions indicating improvement. The Baseline value will be the last measurement collected prior to the first dose of investigational product.Change from Baseline is calculated as the post-dose visit value minus the Baseline value. Mean change from Baseline in SGRQ score at Week 52 has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean COPD Assessment Test (CAT) Score</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The CAT is an 8-item questionnaire developed for use in routine clinical practice to measure the health status of participants with COPD. Each question is assessed on a 6-point scale ranging from 0 (no impairment) to 5 (maximum impairment) with the CAT score ranging from 0-40. Higher scores indicate greater disease impact with reductions indicating improvement. The Baseline value will be the last measurement collected prior to the first dose of investigational product. Change from Baseline is calculated as the post-dose visit value minus the Baseline value. Mean change from Baseline in CAT score at Week 52 has been presented.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">674</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive 300 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive placebo (0.9percent sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) their baseline standard of care COPD medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepolizumab</intervention_name>
    <description>Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile 0.9percent sodium chloride solution</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD diagnosis: Subjects with a clinically documented history of COPD for at least 1
             year in accordance with the following definition by the American Thoracic
             Society/European Respiratory Society

          -  Severity of COPD: Subjects must present with the following: a measured pre and
             post-salbutamol Forced expiratory volume in one second/ Forced vital capacity
             (FEV1/FVC) ratio of &lt;0.70 at Visit 1 to confirm the diagnosis of COPD; a measured
             post-salbutamol FEV1&gt; 20 percent and &lt;=80 percent of predicted normal values
             calculated using National Health and Nutrition Examination Survey (NHANES) III
             reference equations at Visit 1

          -  History of exacerbations: A well documented history (e.g., medical record
             verification) in the 12 months prior to Visit 1 of ; at least two moderate COPD
             exacerbations. Moderate is defined as the use of systemic corticosteroids
             (intramuscular (IM), intravenous, or oral) and/or treatment with antibiotics or; at
             least one severe COPD exacerbation. Severe is defined as having required
             hospitalization. Note: At least one exacerbation must have occurred while the subject
             was taking Inhaled corticosteroid (ICS) plus long acting beta2-agonist (LABA) plus
             long acting muscarinic antagonist (LAMA). Prior use of antibiotics alone does not
             qualify as a moderate exacerbation unless the use was specifically for the treatment
             of worsening symptoms of COPD.

          -  Concomitant COPD therapy: A well documented requirement for optimized standard of care
             background therapy that includes Inhaled corticosteroid (ICS) plus 2 additional COPD
             medications (i.e., triple therapy) for the 12 months prior to Visit 1 and meets the
             following criteria: Immediately prior to Visit 1, minimum of 3 months of use of an;
             Inhaled corticosteroid at a dose &gt;= 500 micrograms (mcg)/day fluticasone propionate
             dose equivalent plus; LABA and LAMA.

        For subjects who are not continually maintained on ICS plus LABA plus LAMA for the entire
        12 months prior to Visit 1 use of following is allowed (but not in the 3 months immediately
        prior to Visit 1); inhaled corticosteroid at a dose &gt;=500 mcg/day fluticasone propionate
        dose equivalent plus; a LABA or a LAMA and; use of at least one other class of COPD
        medication (i.e., phosphodiesterase-4-inhibitors, methylxanthines, or a combination of
        short acting beta2-agonist and short acting muscarinic antagonist).

          -  Informed Consent: Able to give written informed consent prior to participation in the
             study, which will include the ability to comply with the requirements and restrictions
             listed in the consent form. Subjects must be able to read, comprehend, and write at a
             level sufficient to complete study related materials.

          -  Gender: Male or Eligible Female; To be eligible for entry into the study females of
             child bearing potential must commit to consistent and correct use of an acceptable
             method of birth control from the time of consent, for the duration of the trial, and
             for 4 months after last study drug administration.

          -  Age: At least 40 years of age at Visit 1

          -  Smoking status: Subject with confirmed COPD are eligible to participate independent of
             their smoking status and smoking history, i.e. current smokers, never smokers or
             ex-smokers can be enrolled into the study. Current smokers are defined as those with a
             history of cigarette smoking of &gt;=10 pack-years [number of pack years = (number of
             cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10
             years, or 10 cigarettes per day for 20 years)]. Former smokers are defined as those
             who meet the definition of a current smoker but have stopped smoking for at least 6
             months prior to Visit 1. Never smokers are those that do not meet the definition of a
             current or former smoker.

          -  French subjects: In France, a subject will be eligible for inclusion in this study
             only if either affiliated to or a beneficiary of a social security category.

        Exclusion Criteria:

          -  Subjects with Asthma: Current and Former Smokers: Subjects with a current diagnosis of
             asthma (those with a prior history are eligible if they meet inclusion criteria for a
             current diagnosis of COPD); Never-Smokers: Subjects with any history of asthma.

          -  Other respiratory disorders: The investigator must judge that COPD is the primary
             diagnosis accounting for the clinical manifestations of the lung disease. Subjects
             with alpha1-antitrypsin deficiency as the underlying cause of COPD are excluded. Also,
             excluded are subjects with active tuberculosis, lung cancer, bronchiectasis,
             sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung diseases
             or other active pulmonary diseases. Subjects are also excluded if maintenance use of
             bi-level positive airway pressure is required for the treatment of respiratory
             disorder.

          -  COPD stability: Subjects with pneumonia, exacerbation, lower respiratory infection
             within the 4 weeks prior to Visit 1.

          -  Lung resection: Subjects with lung volume reduction surgery within the 12 months prior
             to Visit 1.

          -  Pulmonary rehabilitation program: Participation in the acute phase of a pulmonary
             rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the
             maintenance phase of a pulmonary rehabilitation program are not excluded.

          -  Oxygen: Subjects receiving treatment with oxygen more than 4.0 liters/minute (L/min).
             While breathing supplemental oxygen, subjects should demonstrate an oxyhemoglobin
             saturation greater than or equal to 89 percent.

          -  12-lead Electrocardiography (ECG) finding: An abnormal and significant ECG finding
             from the 12-lead ECG conducted at Visit 1, if considered to be clinically significant
             by the Investigator. 12-lead ECGs will be over-read by a centralized independent
             cardiologist to assist in consistent evaluation of subject eligibility. Results from
             the 12-lead ECG over-read must be received prior to assessing eligibility at Visit 2.

          -  Unstable or life threatening cardiac disease: Subjects with any of the following would
             be excluded: Myocardial infarction or unstable angina in the last 6 months ; Unstable
             or life threatening cardiac arrhythmia requiring intervention in the last 3 months ;
             New York Heart Association (NYHA) Class IV Heart failure

          -  Other diseases/abnormalities: Subjects with (historical or) current evidence of
             clinically significant, neurological, psychiatric, renal, hepatic, immunological,
             endocrine (including uncontrolled diabetes or thyroid disease) or haematological
             abnormalities that are uncontrolled. Significant is defined as any disease that, in
             the opinion of the investigator, would put the safety of the subject at risk through
             participation, or which would affect the efficacy or safety analysis if the
             disease/condition exacerbated during the study.

          -  Eosinophilic disease: Subjects with other conditions that could lead to elevated
             eosinophils such as Hypereosinophilic syndromes including Eosinophilic Granulomatosis
             with Polyangiitis (EGPA, also known as Churg-Strauss Syndrome), or Eosinophilic
             Esophagitis.

          -  Parasitic infection: Subjects with a pre-existing helminthes infestation within 6
             months prior to Visit 1 are also excluded.

          -  Malignancy: A current malignancy or previous history of cancer in remission for less
             than 12 months prior to Visit 1 (Subjects that had localized carcinoma of the skin or
             cervix which was resected for cure will not be excluded). South Korea subjects with a
             diagnosis of malignancy within 5 years of Visit 1 are excluded.

          -  Immunodeficiency: A known immunodeficiency (e.g. human immunodeficiency virus HIV),
             other than that explained by the use of corticosteroids taken for COPD.

          -  Liver disease: Unstable liver disease (as defined by the presence of ascites,
             encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices, or
             persistent jaundice), cirrhosis, and known biliary abnormalities (with the exception
             of Gilbert's syndrome or asymptomatic gallstones). Chronic stable hepatitis B and C
             are acceptable if subject otherwise meets entry criteria (e.g., presence of hepatitis
             B surface antigen or positive hepatitis C test result within 3 months of screening)

          -  Monoclonal antibodies: Subjects who have received any monoclonal antibody within 5
             half-lives of Visit 1.

          -  Investigational medications: Subjects who have received an investigational drug within
             30 days of Visit 1, or within 5 drug half-lives of the investigational drug, whichever
             is longer (this also includes investigational formulations of a marketed product).

          -  Hypersensitivity: Subjects with a known allergy or intolerance to another monoclonal
             antibody or biologic including history of anaphylaxis to another biologic

          -  Inability to read: In the opinion of the investigator, any subject who is unable to
             read and/or would not be able to complete study related materials.

          -  Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study
             procedures. Any infirmity, disability, or geographic location that would limit
             compliance for scheduled visits.

          -  Questionable validity of consent: Subjects with a history of psychiatric disease,
             intellectual deficiency, poor motivation or other conditions that will limit the
             validity of informed consent to participate in the study.

          -  Drug or alcohol abuse: A known or suspected history of alcohol or drug abuse within 2
             years prior to Visit 1.

          -  Previous participation: Subjects who have previously participated in any study of
             mepolizumab.

          -  Affiliation with Investigator Site: Is an investigator, sub-investigator, study
             coordinator, employee of a participating investigator or study site, or immediate
             family member of the aforementioned that is involved in this study.

        Randomization Criteria

        In order to be randomized to study drug the subject must meet the following randomization
        criteria at Visit 2:

          -  Blood eosinophils: Documented elevated peripheral blood eosinophil count of &gt;=300
             cells/microliter within the past 12 months prior to Visit 1; OR A peripheral baseline
             blood eosinophil count of &gt;=150 cells/microliter from haematology conducted at Visit 1

          -  Electronic Diary Compliance: Compliance with completion of the eDiary defined as
             completion of all questions on 5 or more days out of the 7 days immediately preceding
             Visit 2.

          -  12-lead ECG: No evidence of an abnormal and significant ECG finding from the 12-lead
             ECG conducted at Visit 1 as indicated on the over-read provided by the centralized
             independent cardiologist. Subjects with a QT interval corrected with Fridericia's
             formulas (QTcF)&gt;=450 msec are not eligible. For subjects with a QRS interval
             &gt;=120msec, those with QTcF&gt;=480 msec are not eligible. Specific ECG findings that
             preclude subject eligibility are listed in the protocol.

          -  Abnormal chest X-ray (or Computerized Tomography [CT] scan): No chest X-ray (or CT
             scan) that reveals evidence of clinically significant abnormalities not believed to be
             due to the presence of COPD. If a chest X-ray or CT scan is not available within 6
             months prior to Visit 1, then a chest X-ray must be taken at Visit 1 and the results
             reviewed prior to randomization. For sites in Germany: If a chest X-ray (or CT scan)
             within 6 months prior to Screening (Visit 1) is not available, the subject will not be
             eligible for the study.

          -  Laboratory abnormality: No evidence of clinically significant abnormality in the
             haematological, biochemical, or urinalysis screen at Visit 1, as judged by the
             investigator.

          -  Hepatitis B: Subjects who are HBsAg positive or HBcAb positive must not have a HBV DNA
             level &gt;=2000 International Units (IU)/millilitre (mL).

          -  Liver function test: Subjects must meet the following based on results from sample
             taken at Visit 1: Alanine aminotransferase (ALT) &lt;2x ULN (upper limit of normal);
             Alkaline Phosphatase (Alk Phos) &lt;=2x ULN; Bilirubin &lt;=1.5x ULN (isolated
             bilirubin&gt;1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin &lt;35
             percent)

          -  Pregnancy: No subjects who are pregnant or breastfeeding. Subjects should not be
             enrolled if they plan to become pregnant during the time of study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Broomfield</city>
        <state>Colorado</state>
        <zip>80023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adairsville</city>
        <state>Georgia</state>
        <zip>30103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oaks</city>
        <state>Pennsylvania</state>
        <zip>19456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406-7108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bahía Blanca</city>
        <state>Buenos Aires</state>
        <zip>B8000AAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berazategui</city>
        <zip>1886</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425BEN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500CCG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Charles-Borromée</city>
        <state>Quebec</state>
        <zip>J6E 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Talca</city>
        <state>Región Del Maule</state>
        <zip>3460001</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>7500692</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>7860406</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>8242238</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Valparaíso</state>
        <zip>2341131</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>7500698</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>8380453</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kobenhavn NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70378</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ruedersdorf</city>
        <state>Brandenburg</state>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neu-Isenburg</city>
        <state>Hessen</state>
        <zip>63263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ehime</city>
        <zip>791-0281</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukui</city>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1394</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gifu</city>
        <zip>509-6134</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>722-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>053-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagawa</city>
        <zip>762-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>227-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-1196</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mie</city>
        <zip>515-8544</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>983-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>986-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oita</city>
        <zip>876-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>702-8055</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>711-0921</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okinawa</city>
        <zip>901-2121</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>573-0153</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shimane</city>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>436-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>438-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>136-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>152-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>204-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anyang-Si Gyeonggi-do</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucheon city, Gyenggi-do</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cheongju, Chungcheongbuk-do</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daegu</city>
        <zip>705-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>403-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jeonju-si</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul,</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>140-743</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wonju-si, Kanwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Den Bosch</city>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Horn</city>
        <zip>6085 NM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sittard-geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Codlea</city>
        <zip>505100</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Craiova</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Focsani</city>
        <zip>620043</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700115</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pitesti</city>
        <zip>110084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ploiesti</city>
        <zip>100024</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300310</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Humenne</city>
        <zip>066 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sala</city>
        <zip>927 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <zip>052 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vrable</city>
        <zip>952 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>824</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tau-Yuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49051</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mykolayiv</city>
        <zip>54003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stevenage</city>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2014</study_first_posted>
  <results_first_submitted>January 12, 2018</results_first_submitted>
  <results_first_submitted_qc>March 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2018</results_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>exacerbations</keyword>
  <keyword>SB240563</keyword>
  <keyword>mepolizumab</keyword>
  <keyword>eosinophils</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with chronic obstructive pulmonary disease (COPD) with frequent exacerbations, on high dose inhaled corticosteroid (ICS)-based triple inhaled maintenance therapy were included. Participants were randomized to receive mepolizumab (100 or 300 milligrams [mg]) or placebo by subcutaneous (SC) injection every 4 weeks for up to 52 weeks.</recruitment_details>
      <pre_assignment_details>A total of 674 participants were randomized and received at least one dose of study treatment and were included in the modified intent to treat (mITT) population. One participant randomized to the mepolizumab 300 mg group was withdrawn without receiving study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Eligible participants were randomized to and received placebo by SC injection every 4 weeks for up to 52 weeks in addition to their standard of care (SoC) therapy. Salbutamol metered dose inhaler (MDI) was issued for use as rescue medication throughout the study.</description>
        </group>
        <group group_id="P2">
          <title>Mepolizumab 100 mg SC</title>
          <description>Eligible participants were randomized to and received mepolizumab 100 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
        </group>
        <group group_id="P3">
          <title>Mepolizumab 300 mg SC</title>
          <description>Eligible participants were randomized to and received mepolizumab 300 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="223"/>
                <participants group_id="P3" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Investigational Product (IP)</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Not Completed IP</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew IP Due to: Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew IP Due to: Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew IP Due to: Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew IP Due to: Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew IP Due to: Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew IP Due to: Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew IP Due to: Withdrawal by Subj.</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew IP Due to: Site Closed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Eligible participants were randomized to and received placebo by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
        </group>
        <group group_id="B2">
          <title>Mepolizumab 100 mg SC</title>
          <description>Eligible participants were randomized to and received mepolizumab 100 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
        </group>
        <group group_id="B3">
          <title>Mepolizumab 300 mg SC</title>
          <description>Eligible participants were randomized to and received mepolizumab 300 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="226"/>
            <count group_id="B2" value="223"/>
            <count group_id="B3" value="225"/>
            <count group_id="B4" value="674"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="8.64"/>
                    <measurement group_id="B2" value="64.8" spread="9.06"/>
                    <measurement group_id="B3" value="64.8" spread="8.96"/>
                    <measurement group_id="B4" value="65.1" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race customized</title>
              <category_list>
                <category>
                  <title>Asian-Central/South Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian-East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian-Japanese Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian-South East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White-White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="182"/>
                    <measurement group_id="B4" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Moderate or Severe Exacerbations</title>
        <description>Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (&gt;=24 hours) or result in death. Moderate and severe exacerbations occurring from the start of investigational product (IP) up to the Week 52 visit, including exacerbations reported after early discontinuation from IP by participants who remained in the study, were included in the analysis. The analysis was performed on the modified intent-to-treat (mITT) Population (all randomized participants who received at least one dose of study treatment).</description>
        <time_frame>From randomization to Week 52</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants were randomized to and received placebo by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Mepolizumab 100 mg SC</title>
            <description>Eligible participants were randomized to and received mepolizumab 100 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Mepolizumab 300 mg SC</title>
            <description>Eligible participants were randomized to and received mepolizumab 100 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Moderate or Severe Exacerbations</title>
          <description>Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (&gt;=24 hours) or result in death. Moderate and severe exacerbations occurring from the start of investigational product (IP) up to the Week 52 visit, including exacerbations reported after early discontinuation from IP by participants who remained in the study, were included in the analysis. The analysis was performed on the modified intent-to-treat (mITT) Population (all randomized participants who received at least one dose of study treatment).</description>
          <population>mITT Population</population>
          <units>Moderate/severe exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="1.29" upper_limit="1.72"/>
                    <measurement group_id="O2" value="1.19" lower_limit="1.02" upper_limit="1.38"/>
                    <measurement group_id="O3" value="1.27" lower_limit="1.09" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.068</p_value>
            <p_value_desc>Adjusted p-value; Family wise type I error controlled within each endpoint using a Hochberg testing procedure</p_value_desc>
            <method>Negative binomial model</method>
            <param_type>Rate ratio (Mepolizumab 100/Placebo)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Analysis using a negative binomial model with covariates of treatment, geographic region, no. of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1, smoking status and offset of log (time in on- and off- treatment period)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Negative binomial model</method>
            <param_type>Rate ratio (Mepolizumab 100/Placebo)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Analysis using a negative binomial model with covariates of treatment, geographic region, no. of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1, smoking status and offset of log (time in on- and off- treatment period)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <p_value_desc>Adjusted p-value; Family wise type I error controlled within each endpoint using a Hochberg testing procedure</p_value_desc>
            <method>Negative binomial model</method>
            <param_type>Rate ratio (Mepolizumab 300/Placebo)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Analysis using a negative binomial model with covariates of treatment, geographic region, no. of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1, smoking status and offset of log (time in on- and off- treatment period</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Negative binomial model</method>
            <param_type>Rate ratio (Mepolizumab 300/Placebo)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Analysis using a negative binomial model with covariates of treatment, geographic region, no. of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1, smoking status and offset of log (time in on- and off- treatment period)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Moderate/Severe Exacerbation</title>
        <description>Kaplan Meier estimates of the probability of a moderate or severe exacerbation are expressed as the percentage of participants with an exacerbation over time (by Week 8, 16, 24, 32, 40, 48, 52). Analysis of time to first moderate/severe exacerbation was performed on the mITT population and included exacerbations reported on-treatment and those reported after early discontinuation from IP by participants who remained in the study.</description>
        <time_frame>From randomization to Week 52</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants were randomized to and received placebo by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Mepolizumab 100 mg SC</title>
            <description>Eligible participants were randomized to and received mepolizumab 100 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Mepolizumab 300 mg SC</title>
            <description>Eligible participants were randomized to and received mepolizumab 300 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Moderate/Severe Exacerbation</title>
          <description>Kaplan Meier estimates of the probability of a moderate or severe exacerbation are expressed as the percentage of participants with an exacerbation over time (by Week 8, 16, 24, 32, 40, 48, 52). Analysis of time to first moderate/severe exacerbation was performed on the mITT population and included exacerbations reported on-treatment and those reported after early discontinuation from IP by participants who remained in the study.</description>
          <population>mITT Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" lower_limit="17.7" upper_limit="28.6"/>
                    <measurement group_id="O2" value="22.9" lower_limit="17.9" upper_limit="29.0"/>
                    <measurement group_id="O3" value="18.3" lower_limit="13.8" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="34.6" upper_limit="47.5"/>
                    <measurement group_id="O2" value="36.0" lower_limit="30.0" upper_limit="42.6"/>
                    <measurement group_id="O3" value="29.0" lower_limit="23.5" upper_limit="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1" lower_limit="44.6" upper_limit="57.8"/>
                    <measurement group_id="O2" value="42.4" lower_limit="36.2" upper_limit="49.2"/>
                    <measurement group_id="O3" value="36.7" lower_limit="30.8" upper_limit="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3" lower_limit="51.8" upper_limit="64.9"/>
                    <measurement group_id="O2" value="46.1" lower_limit="39.8" upper_limit="52.9"/>
                    <measurement group_id="O3" value="44.9" lower_limit="38.7" upper_limit="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" lower_limit="55.8" upper_limit="68.7"/>
                    <measurement group_id="O2" value="50.8" lower_limit="44.4" upper_limit="57.6"/>
                    <measurement group_id="O3" value="51.8" lower_limit="45.4" upper_limit="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2" lower_limit="57.8" upper_limit="70.6"/>
                    <measurement group_id="O2" value="55.5" lower_limit="49.1" upper_limit="62.2"/>
                    <measurement group_id="O3" value="58.3" lower_limit="51.9" upper_limit="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="60.2" upper_limit="73.1"/>
                    <measurement group_id="O2" value="57.9" lower_limit="51.5" upper_limit="64.5"/>
                    <measurement group_id="O3" value="58.8" lower_limit="52.4" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <p_value_desc>Adjusted p-value; Family wise type I error controlled within each endpoint using a Hochberg testing procedure</p_value_desc>
            <method>Cox Proportional Hazards Model</method>
            <param_type>Hazard Ratio(Mepolizumab 100/Placebo)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Analysis performed using a Cox Proportional Hazards Model with covariates of treatment, geographic region, number of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1 and smoking status</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.103</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Cox Proportional Hazards Model</method>
            <param_type>Hazard Ratio (Mepolizumab/Placebo)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Analysis performed using a Cox Proportional Hazards Model with covariates of treatment, geographic region, number of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1 and smoking status</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <p_value_desc>Adjusted p-value; Family wise type I error controlled within each endpoint using a Hochberg testing procedure</p_value_desc>
            <method>Cox Proportional Hazards Model</method>
            <param_type>Hazard Ratio (Mepolizumab 300/Placebo)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>Analysis performed using a Cox Proportional Hazards Model with covariates of treatment, geographic region, number of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1 and smoking status</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.030</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Cox Proportional Hazards Model</method>
            <param_type>Hazard Ratio (Mepolizumab 300/Placebo)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>Analysis performed using a Cox Proportional Hazards Model with covariates of treatment, geographic region, number of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1 and smoking status</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of COPD Exacerbations Requiring Emergency Department (ED) Visits and/or Hospitalizations (Hosp)</title>
        <description>COPD exacerbations requiring an ED visit and/or hosp occurring from the start of IP up to the Week 52 visit, including exacerbations reported after early discontinuation from IP by participants who remained in the study, were included in the analysis. This analysis was performed on the mITT population.</description>
        <time_frame>From randomization to Week 52</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants were randomized to and received placebo by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Mepolizumab 100 mg SC</title>
            <description>Eligible participants were randomized to and received mepolizumab 100 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Mepolizumab 300 mg SC</title>
            <description>Eligible participants were randomized to and received mepolizumab 300 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of COPD Exacerbations Requiring Emergency Department (ED) Visits and/or Hospitalizations (Hosp)</title>
          <description>COPD exacerbations requiring an ED visit and/or hosp occurring from the start of IP up to the Week 52 visit, including exacerbations reported after early discontinuation from IP by participants who remained in the study, were included in the analysis. This analysis was performed on the mITT population.</description>
          <population>mITT Population</population>
          <units>Exacerbations requiring ED/hosp per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" lower_limit="0.20" upper_limit="0.40"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.11" upper_limit="0.25"/>
                    <measurement group_id="O3" value="0.23" lower_limit="0.16" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <p_value_desc>Adjusted p-value; Family wise type I error controlled within each endpoint using a Hochberg testing procedure</p_value_desc>
            <method>Negative binomial model</method>
            <param_type>Rate ratio (Mepolizumab 100/Placebo)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Analysis using a negative binomial model with covariates of treatment, geographic region, no. of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1, smoking status and offset of log (time in on- and off- treatment period)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.042</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Negative binomial model</method>
            <param_type>Rate ratio (Mepolizumab 100/Placebo)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Analysis using a negative binomial model with covariates of treatment, geographic region, no. of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1, smoking status and offset of log (time in on- and off- treatment period)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.447</p_value>
            <p_value_desc>Adjusted p-value; Family wise type I error controlled within each endpoint using a Hochberg testing procedure</p_value_desc>
            <method>Negative binomial model</method>
            <param_type>Rate ratio (Mepolizumab 300/Placebo)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>Analysis using a negative binomial model with covariates of treatment, geographic region, no. of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1, smoking status and offset of log (time in on- and off- treatment period)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.447</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Negative binomial model</method>
            <param_type>Rate ratio (Mepolizumab 300/Placebo)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>Analysis using a negative binomial model with covariates of treatment, geographic region, no. of moderate/severe exacerbations in previous year, Baseline percent predicted FEV1, smoking status and offset of log (time in on- and off- treatment period)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Total St. George’s Respiratory Questionnaire (SGRQ) Score</title>
        <description>The SGRQ for COPD is a 40-item questionnaire derived from the original SGRQ , designed to measure health impairment by addressing the frequency of respiratory symptoms and current state of the participant. SGRQ Total Scores range from 0 to 100 with higher scores indicating worse health-related quality of life and reductions indicating improvement. The Baseline value will be the last measurement collected prior to the first dose of investigational product.Change from Baseline is calculated as the post-dose visit value minus the Baseline value. Mean change from Baseline in SGRQ score at Week 52 has been presented.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT Population. Participants analyzed represents those with a Baseline and at least one post-Baseline assessment, and with no missing covariates.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants were randomized to and received placebo by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Mepolizumab 100 mg SC</title>
            <description>Eligible participants were randomized to and received mepolizumab 100 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Mepolizumab 300 mg SC</title>
            <description>Eligible participants were randomized to and received mepolizumab 300 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Total St. George’s Respiratory Questionnaire (SGRQ) Score</title>
          <description>The SGRQ for COPD is a 40-item questionnaire derived from the original SGRQ , designed to measure health impairment by addressing the frequency of respiratory symptoms and current state of the participant. SGRQ Total Scores range from 0 to 100 with higher scores indicating worse health-related quality of life and reductions indicating improvement. The Baseline value will be the last measurement collected prior to the first dose of investigational product.Change from Baseline is calculated as the post-dose visit value minus the Baseline value. Mean change from Baseline in SGRQ score at Week 52 has been presented.</description>
          <population>mITT Population. Participants analyzed represents those with a Baseline and at least one post-Baseline assessment, and with no missing covariates.</population>
          <units>Score on SGRQ scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="0.98"/>
                    <measurement group_id="O2" value="-5.0" spread="0.95"/>
                    <measurement group_id="O3" value="-3.3" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.447</p_value>
            <p_value_desc>Adjusted p-value; Family wise type I error controlled within each endpoint using a Hochberg testing procedure</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Mean difference(Mepolizumab 100-Placebo)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Analysis performed using mixed model repeated measures with covariates of Baseline SGRQ total score, geographic region, smoking status, treatment and visit, plus interaction terms for visit by Baseline and visit by treatment group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.180</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Mean difference(Mepolizumab 100-Placebo)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Analysis performed using mixed model repeated measures with covariates of Baseline SGRQ total score, geographic region, smoking status, treatment and visit, plus interaction terms for visit by Baseline and visit by treatment group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.926</p_value>
            <p_value_desc>Adjusted p-value; Family wise type I error controlled within each endpoint using a Hochberg testing procedure</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Mean difference(Mepolizumab 300-Placebo)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>Analysis performed using mixed model repeated measures with covariates of Baseline SGRQ total score, geographic region, smoking status, treatment and visit, plus interaction terms for visit by Baseline and visit by treatment group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.926</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Mean difference(Mepolizumab 300-Placebo)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>Analysis performed using mixed model repeated measures with covariates of Baseline SGRQ total score, geographic region, smoking status, treatment and visit, plus interaction terms for visit by Baseline and visit by treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean COPD Assessment Test (CAT) Score</title>
        <description>The CAT is an 8-item questionnaire developed for use in routine clinical practice to measure the health status of participants with COPD. Each question is assessed on a 6-point scale ranging from 0 (no impairment) to 5 (maximum impairment) with the CAT score ranging from 0-40. Higher scores indicate greater disease impact with reductions indicating improvement. The Baseline value will be the last measurement collected prior to the first dose of investigational product. Change from Baseline is calculated as the post-dose visit value minus the Baseline value. Mean change from Baseline in CAT score at Week 52 has been presented.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT Population. Participants analyzed represents those with a Baseline and at least one post-Baseline assessment, and with no missing covariates.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants were randomized to and received placebo by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Mepolizumab 100 mg SC</title>
            <description>Eligible participants were randomized to and received mepolizumab 100 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Mepolizumab 300 mg SC</title>
            <description>Eligible participants were randomized to and received mepolizumab 300 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean COPD Assessment Test (CAT) Score</title>
          <description>The CAT is an 8-item questionnaire developed for use in routine clinical practice to measure the health status of participants with COPD. Each question is assessed on a 6-point scale ranging from 0 (no impairment) to 5 (maximum impairment) with the CAT score ranging from 0-40. Higher scores indicate greater disease impact with reductions indicating improvement. The Baseline value will be the last measurement collected prior to the first dose of investigational product. Change from Baseline is calculated as the post-dose visit value minus the Baseline value. Mean change from Baseline in CAT score at Week 52 has been presented.</description>
          <population>mITT Population. Participants analyzed represents those with a Baseline and at least one post-Baseline assessment, and with no missing covariates.</population>
          <units>Score on CAT scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.42"/>
                    <measurement group_id="O2" value="-1.6" spread="0.42"/>
                    <measurement group_id="O3" value="-0.8" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.926</p_value>
            <p_value_desc>Adjusted p-value; Family wise type I error controlled within each endpoint using a Hochberg testing procedure</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Mean difference(Mepolizumab 100-Placebo)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>Analysis performed using mixed model repeated measures with covariates of Baseline CAT score, geographic region, smoking status, treatment and visit, plus interaction terms for visit by Baseline and visit by treatment group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.055</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Mean difference(Mepolizumab 100-Placebo)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>Analysis performed using mixed model repeated measures with covariates of Baseline CAT score, geographic region, smoking status, treatment and visit, plus interaction terms for visit by Baseline and visit by treatment group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.926</p_value>
            <p_value_desc>Adjusted p-value; Family wise type I error controlled within each endpoint using a Hochberg testing procedure</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Mean difference(Mepolizumab 300-Placebo)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Analysis performed using mixed model repeated measures with covariates of Baseline CAT score, geographic region, smoking status, treatment and visit, plus interaction terms for visit by Baseline and visit by treatment group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.547</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Mean difference(Mepolizumab 300-Placebo)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Analysis performed using mixed model repeated measures with covariates of Baseline CAT score, geographic region, smoking status, treatment and visit, plus interaction terms for visit by Baseline and visit by treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) collected from the start of study participation until the end of follow up (up to Week 60). On-treatment non-serious adverse events (AEs) reported from start of study treatment until 4 weeks after last dose.</time_frame>
      <desc>AEs and SAEs were collected in Safety Population which comprised of all randomized participants who received at least one dose of study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Eligible participants were randomized to and received placebo by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
        </group>
        <group group_id="E2">
          <title>Mepolizumab 100 mg SC</title>
          <description>Eligible participants were randomized to and received mepolizumab 100 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
        </group>
        <group group_id="E3">
          <title>Mepolizumab 300 mg SC</title>
          <description>Eligible participants were randomized to and received mepolizumab 300 mg by SC injection every 4 weeks for up to 52 weeks in addition to their SoC therapy. Salbutamol MDI was issued for use as rescue medication throughout the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="226"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="223"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Injection related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haematocrit increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="52" subjects_affected="37" subjects_at_risk="226"/>
                <counts group_id="E2" events="34" subjects_affected="25" subjects_at_risk="223"/>
                <counts group_id="E3" events="54" subjects_affected="32" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="223"/>
                <counts group_id="E3" events="12" subjects_affected="8" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="223"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="223"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E3" events="27" subjects_affected="11" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E3" events="17" subjects_affected="12" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="223"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="65" subjects_affected="48" subjects_at_risk="226"/>
                <counts group_id="E2" events="57" subjects_affected="39" subjects_at_risk="223"/>
                <counts group_id="E3" events="52" subjects_affected="40" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="226"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="223"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="223"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E3" events="15" subjects_affected="11" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="223"/>
                <counts group_id="E3" events="21" subjects_affected="17" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="226"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="223"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="20" subjects_at_risk="226"/>
                <counts group_id="E2" events="62" subjects_affected="34" subjects_at_risk="223"/>
                <counts group_id="E3" events="39" subjects_affected="22" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="226"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E3" events="22" subjects_affected="16" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="226"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="223"/>
                <counts group_id="E3" events="17" subjects_affected="10" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="223"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E3" events="24" subjects_affected="10" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

